NeurAxis Secures $5 Million in Direct Stock Offering for Growth

Author: Addison Perry Updated: 05-22-2025 01:15 PM

NeurAxis Closes $5 Million Direct Stock Offering

NeurAxis, Inc. (NYSE American: NRXS), a leader in medical technology focused on innovative neuromodulation therapies, has successfully closed a direct registered offering of 1,538,461 common stock shares priced at $3.25 each. This strategic move has successfully generated gross proceeds of approximately $5 million, enhancing the company’s financial stability and positioning for future growth.

Significance of the Funding

Brian Carrico, NeurAxis’s President and CEO, expressed that this financing milestone, in conjunction with the recent FDA clearance for IB-Stim to treat Pediatric Functional Abdominal Pain (FAP), is critical for the company's future. The $5.0 million influx of capital, along with over $1 million raised through warrant exercises, significantly bolsters their balance sheet as they head into the next stages of revenue generation for IB-Stim. Notably, the upcoming implementation of their CPT Category I code, effective on January 1, 2026, is aimed at expanding access to their treatments, which is especially important considering the scarcity of FDA-approved medications for pediatric abdominal pain disorders linked to gut-brain interactions.

The Role of Craig-Hallum Capital Group

Craig-Hallum Capital Group played a crucial role as the exclusive placement agent during this offering. Their expertise in market dynamics and investor relations has been instrumental for NeurAxis in achieving this successful capital raise.

Future Steps and Clinical Trials

The funds raised will enable NeurAxis to upscale its operations and continue its commitment to the advancement of neuromodulation therapies for chronic conditions. Their flagship product, IB-Stim™, utilizes innovative Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, which has already received FDA clearance for additional treatments. Furthermore, ongoing clinical trials are assessing the efficacy of PENFS in both pediatric and adult patient populations, aiming to address significant unmet healthcare needs.

About NeurAxis, Inc.

NeurAxis, Inc. is dedicated to providing cutting-edge neuromodulation therapies aimed at improving the quality of life for individuals with debilitating chronic conditions. Their commitment to scientific advancement and evidence-based medicine drives the adoption of their proprietary therapies, which provide new options for patients suffering from various health challenges.

Frequently Asked Questions

What amount did NeurAxis raise in this stock offering?

NeurAxis raised approximately $5 million from its recent direct stock offering.

Who acted as the placement agent for NeurAxis’s offering?

Craig-Hallum Capital Group served as the exclusive placement agent for this offering.

What is the significance of FDA clearance for NeurAxis?

The FDA's clearance for IB-Stim treatments marks a pivotal advancement for NeurAxis, allowing them to provide necessary therapies for pediatric patients dealing with abdominal pain.

What is IB-Stim technology?

IB-Stim™ is NeurAxis's exclusive Percutaneous Electrical Nerve Field Stimulation (PENFS) technology designed to treat functional abdominal pain, particularly in children and adolescents.

What future developments can we expect from NeurAxis?

NeurAxis plans to use the funds to continue expanding its product offerings and conducting additional clinical trials to validate the efficacy of its technologies in various conditions.

About The Author

Hello, I'm 30-year-old financial writer and expert Addison Perry, and I love to simplify the intricacies of the financial industry. I've committed myself over the years to deciphering the subtleties of investing techniques and economic trends and converting them into doable guidance that anybody can use. My goal with writings and books is to make money interesting and approachable so that readers may take charge of their financial futures.

My enthusiasm to empowerment and education has propelled me through my career in finance. I write because I think that everyone should be able to make educated financial decisions, and I try to provide that. Regardless of experience level with investing, my work is intended to provide insightful analysis and practical advice to enable you to thrive in the always changing financial environment. I appreciate you traveling with me toward success and financial literacy.

Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.